FDA to piggyback on insurers' databases

Remember that drug-safety database Congress required the FDA to set up? The idea was for the FDA to actively monitor drugs and possible adverse effects, rather than waiting for doctors and drug companies to report problems. Well, the agency is ready to announce its plans--and they don't include setting up a database. Instead, the FDA will contract with insurers, such as WellPoint and UnitedHealth, to scan their members' records for potential problems. The agency also plans to bring other health systems into the effort.

"We're bringing together all these different groups in a network so that we can ask them to look at the same question at the same time," Janet Woodcock (photo), CDER director, told the Wall Street Journal.

The FDA will use the databases to monitor potential problems that showed up in a less-than-statistically-significant way during clinical trials. The insurers and other network participants also will build computer models to detect signals of potential problems that weren't suspected before. To show that it could do so, WellPoint tested its 1999 data and found that it could have spotted the heart-related problems associated with Vioxx within four months of the drug's introduction.

- read the WSJ story

Related Articles:
Bickering may stall trial database. Report
Senate toughens drug safety supervision in PDUFA bill. PDUFA report
PDUFA debate highlights drug safety issues. PDUFA report
FDA taps new-yet-old drug chief. FDA report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.